EP1187615A2 - Immunodepressive effekte von pteridin-derivaten - Google Patents

Immunodepressive effekte von pteridin-derivaten

Info

Publication number
EP1187615A2
EP1187615A2 EP00902660A EP00902660A EP1187615A2 EP 1187615 A2 EP1187615 A2 EP 1187615A2 EP 00902660 A EP00902660 A EP 00902660A EP 00902660 A EP00902660 A EP 00902660A EP 1187615 A2 EP1187615 A2 EP 1187615A2
Authority
EP
European Patent Office
Prior art keywords
dimethyl
dimethyllumazine
lumazine
pharmaceutical composition
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00902660A
Other languages
English (en)
French (fr)
Inventor
Mark Jozef Albert Waer
Piet André Maurits Maria HERDEWIJN
Wolfgang Eugen Pfleiderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4 AZA IP NV
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of EP1187615A2 publication Critical patent/EP1187615A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the invention relates to a pharmaceutical composition for the treatment of autoimmuno disorders and/or the treatment or prevention of transplant- rejections comprising pteridine derivatives.
  • the invention further relates to combined pharmaceutical preparations comprising one or more pteridine derivates and one or more known immunosuppressan , and to a group of novel pteridine derivates as such. Further the invention is also related to a method for the treatment of autoimmuno disorders and/or of transplant-rejections.
  • pteridine derivates are known in nature and used in the preparation of medicines, for example as described in EP-A-108 890.
  • Other medical uses of derivatives of pteridine are described in WO 95-31987 as NO-synthase inhibitors, for example for the treatment of diseases caused by a high nitrogen monoxide level .
  • WO-95-32203 describes also the use of tetrahydropteridine derivatives as NO-synthase inhibitors .
  • a first object of the invention is to provide a pharmaceutical composition having high immunosuppressive activity.
  • Another object of the invention is to provide a combined immunosuppressive preparation which causes a superadditive effect, comprising a pteridine derivative of the invention and other known immunosuppressants .
  • Another further object of the invention is to provide immunosuppressive compounds, which are active in a minor dose, in order to decrease the considerable treatment costs.
  • Known immunosuppressive compounds are for example cyclosporine A, subsituted xanthines, tacrolimus (FK 506) , rapamycine (RPM) , leflunomide, mofetil, adrenocortical steroids, cytotoxic drugs and antibody preparations .
  • CyA cyclosporine A
  • Methylxanthines for example pentoxifylline (PTX) , are known having immunosuppressive effects in vitro.
  • PTX pentoxifylline
  • the present invention relates in particular to the application of a group pteridine derivatives and their pharmaceutical salts, possessing unexpectedly desirable pharmaceutical properties, i.e. are highly active immunosuppressive agents .
  • the invention demonstrates the immunosuppressive effects of pharmaceutical composition for the treatment of autoimmuno disorders and/or for the treatment or prevention of transplant-rejections comprising a pteridine derivative of general formula:
  • R and R are independently hydrogen,- aliphatic saturated or unsaturated; straight or branched carbon chain with 1 to 7 carbon atoms; substituted or unsubstituted aryl or alkylaryl substituents, whereby the carbon atoms may be oxidized represented by alcohol or carbonyl function or carboxylic acids and their esters;
  • R 3 and R 4 are independently hydrogen, hydroxyl, halogen, alkyl, haloalkyl, alkoxy, wherein alkyl and the alkyl group may be branched or straight and contains one or four carbon atoms, formyl and derivatives such as hydroxylamino conjugates and acetals, cyano, carboxylic acids and carboxyl acid derivatives such as esters and amides, sulfhydryl, amino, al ylamino, cycloalkylamino, alkenylamino, alkynylamino, benzyla ino, hydroxylalkylamino, morfolinoalkylamino, fenyl ydrazino, morfoline, piperidine, mercaptobenzyl, mercaptoalkyl, cysteinyl ester, styryl, substituted or unsubstituted aromatic ring,- aromatic or heterocyclic substituent substituted with an aliphatic spacer between the
  • X and Y are independently oxygen or sulfur or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier.
  • Preferred pteridine derivatives comprising compositions are given in claims 2-9. Particularly preferred are the compositions according to claim 10.
  • the invention further relates to a combined preparation having synergetic effects containing 1) cyclosporine A, substituted xanthines, tacrolimus (FK506) , Rapa ycin (RPM) , Leflunomide, Mofetil, adrenocortical steriods, cytotoxic drugs and antibody compositions and 2) at least one pteridine derivative of formula (I) defined above, and optionally a pharmaceutical excipient, for simultaneous, separate or sequential use in (auto) immune disorders and/or in the treatment of transplant-rejections.
  • the invention further relates to a method for treating auto-immuno disorders or transplant-rejections in a subject by administering an effective amount of a pharmaceutical composition of claims 1-11, to the compounds as such as defined above, to the use of these compounds for the treatment of autoimmuno disorders and/or the treatment and/or prevention of transplant rejections, and to a method for selecting potent immunosuppressive agents based on the determination of the three parameters MLC, ACD 3 and ACD 28 .
  • 6- (1, 2-Dibromo-2- (methoxycarbonyl) ethyl) -1,3- dimethyllumazine (6) To a solution of 6- [ (E) -2-methoxycarbonylethenyl] lumazine (0.7 g, 2.53 mmoles) in CHC1 3 (20 ml) was added bromine (0.64 g, 4 mmoles) dissolved in CHC1 3 (5 ml) and then the mixture stirred at room temperature for 6 hours . It was evaporated to dryness and the residue treated with MeOH to give a colorless precipitate. The solid was collected, washed with MeOH and dried in a vacuum desiccator. Yield: 0.97 g (88%). M.p.
  • 6- (l-Methoxy-2-methoxycarbonyl) ethenyl) -1,3- dimethy1lumazine (10) A suspension of 6 (0.2 g, 0.46 mmoles) in dry MeOH (8 ml) was treated with a solution of sodium (0.046 g, 2 mmoles) in MeOH (2 ml) at room temperature with stirring for 15 min. Then NH 4 C1 (0.1 g) and H 2 0 (10 ml) were added and the mixture extracted with CHC1 3 (2 x 50 ml) . The organic layer was dried over Na 2 S0 4 , evaporated and the residue crystallized from CHCl 3 /n-hexane. Yield: 0.085 g (60%). M.p. 160°C. UV (MeOH): 204 (4.20); 245 (4.15); 288 (4.23) ; 350 (3.99) .
  • 1, 3 -Dimethyl-6-phenyl-7-mercaptolumazine (28) A mixture of 7-hydroxy-l, -dimethyl-6-phenyllumazine [5] (2.84 g, 0.01 mole) and P 4 S 10 (3.3 g) was heated in pyridine (75 ml) under reflux for 1 hour. After cooling was diluted with H 2 0 (50 ml) and after standing for several hours the yellow precipiptate (28-pyridinium salt, 3.3 g, 87%). The salt was dissolved in hot H 2 0 (100 ml) and acidified by HCl to pH 0. The resulting yellow crystals were collected, washed and dried in the oven.
  • 6-Benzoyl-l, 3-dimethyl-7- (4-methoxyphenyl) lumazine (31) A suspension of 6-benzoyl-7, 8-dihydro-l, 3-dimethyl-7- (4- methoxyphenyl) lumazine (31a) (0.3 g, 0.74 mmoles) in dioxane (40 ml) was treated at room temperature with 1%- KMn0 4 solution (10 ml) by dropwise addition with stirring. After 30 min the excess of KMn0 4 was reduced by NaHS0 3 , the Mn0 2 filtered off, washed with warm EtOH (3 x 20 ml) and then the united organic phases evaporated to dryness.
  • 6-Benzoyl-1, 3-dimethyl-7-phenyllumazine (32) Analogous to procedure 31 from ⁇ -benzoyl-7, 8-dihydro-l, 3- di ethyl- 7 -phenyllumazine (32a) (0.3 g, 0.78 mmoles). Yield: 0.18 g (62%). M.p. 185-187°C. UV (MeOH): 252 (4.39); [290 (4.08)]; 349 (4.16).
  • Various models may be used for testing an immunosuppressive effect.
  • different transplantation models are available. They are strongly influenced by different immunogenicities, depending on the donor and recipient species used and depending on the nature of the transplanted organ. The survival time of transplanted organs can thus be used to measure the suppression of the immune response.
  • lymphocyte activation tests There exist also various models. The most used are lymphocyte activation tests. Usually activation is measured via lymphocyte proliferation. Inhibition of proliferation thus always means immunosuppression under the experimental conditions applied.
  • - CD3 assay here there is an activation of the T- lymphocytes via an exogenously added antibody (OKT3) . This antibody reacts against the CD3 molecule located on the lymphocyte membrane. This molecule has a costimulatory function.
  • OKT3-CD3 results in T-cell activation which proceeds via the Ca 2 +/calmodulin/calcineurin system and can be inhibited by CyA.
  • CD28 assay here specific activation of the T- lymphocyte goes also via an exogenously added antibody against the CD28 molecule. This molecule is also located on the lymphocyte membrane, and delivers strong costimulatory signals. This activation is Ca 2 +-independent and thus cannot be inhibited by CyA.
  • PBMC Peripheral blood mononuclear cells
  • Allogeneic PBMC or EBV-transformed human B cells [RPMI1788 (ATCC name CCL156)] which strongly express B7-1 and B7-2 were used as stimulator cells after irradiation with 30 Gy.
  • MLR was performed in triplicate wells. After 5 days incubation at 37 °C, 1 ⁇ Ci [ 3 H] -thymidine was added to each cup. After a further 16 hours incubation, cells were harvested and counted in a ⁇ -counter.
  • T cells were purified by removing non-T cells. Briefly, monocytes were removed by cold agglutination. The resulting lymphoid cells were further purified by a cell enrichment immunocolumn [Cellect Human T (Biotex, Edmonton, Alberta, Canada)] by a process of negative selection. More than 95% of the B cells were removed with this procedure. After depletion, the resulting T cell preparation was highly purified explaining these cells could not be activated by PHA or rIL-2 alone at concentrations capable of stimulating RBMC prior to deletion.
  • T cell proliferations induced by anti-CD3 mAb + PMA or anti-CD28 mAb + PMA Highly purified T cells (10 6 /ml) were stimulated by immobilized anti-CD3 or anti-CD28 mAb in the presence of PMA.
  • Anti-CD3 mAb (CLB-CD3; CLB, Amsterdam, The Netherlands) were fixed on the 96-microwell plates by incubating the wells with 50 ⁇ l of mAb solution (1/800 dilution in culture medium) .
  • Anti-CD28 mAb (CLB-CD28; CLB, Amsterdam, The Netherlands) 50 ⁇ l (1/650 dilution in culture medium) was added directly to the wells. Further, 20 ⁇ l PMA (Sigma, St.
  • column II shows the IC50 values of the various substances in the MLR.
  • the IC50 value represents the lowest concentration of the substances that resulted in a 50% suppression of the MLR.
  • WBA is a lymphoprolif ⁇ ration assay performed in vitro but using lymphocytes present in whole blood, taken from animals that were previously given test substances in vivo. Hence it reflects the in vivo effect of substances as assessed with an in vitro read-out assay.
  • Rats inbred, male 6- to 8-weeks old R/A rats weighing ⁇ 200 g were used as recipients.
  • Drug administration Pteridine derivatives were dissolved in DMSO and further diluted with PBS. Products were given orally in different concentrations 2 times a day for 2 days. To perform the experiments, 6-8 hours after the last administration 1 ml of blood is taken by heart puncture after ether anesthesia and anticoagulated with 100 U/ml of preservative free heparine.
  • Heparinized whole blood was diluted (1:25) with complete RPMI medium and stimulated with 15 ⁇ g/ml of concanavalin A (Con A) in triplicate wells in 96-well microtiter plates at 37 °C and 5% C0 2 . After 96-h culture, proliferation was determined by measuring the incorporation (cpm) of [ 3 H] -thymidine.
  • MLR mixed lymphocyte reaction
  • autoimmune diseases including diabetes mellitus, multiple sclerosis, glomerulonephritis, rheumatoid arthritis, psoriasis systemic diseases such as vasculitis; scleroderma, polymyositis, autoimmune endocrine disorders (thyroiditis) , ocular diseases (uveitis) , inflammatory bowel diseases (Crohn's disease, colitis ulcerosa) , autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis) autoimmune pneumonitis and auto-immune carditis .
  • autoimmune diseases including diabetes mellitus, multiple sclerosis, glomerulonephritis, rheumatoid arthritis, psoriasis systemic diseases such as vasculitis; scleroderma, polymyositis, autoimmune endocrine disorders (thyroiditis) , ocular diseases (uveitis) , inflammatory bowel diseases (
  • cyclosporine A and FK506 are only active in the anti-CD3 + PMA test
  • the pteridine derivatives according to the invention were active, not only in the anti-CD3 + PMA but also in the anti-CD28 + PMA test. It has been shown that the latter is Ca-calmodulin resistant, and resistant to CsA and FK506.
  • the anti-CD28 + PMA pathway has also been called the cosignal pathway and is important to induce energy and even tolerance in T cells.
  • representative compounds have been found to be active in an whole blood assay.
  • organ in the description is understood all organs or parts of organs (even several) in mammals, in particular humans, for example kidney, heart, skin, liver, muscle, cornea, bone, bone marrow, lung, pancreas, intestine or stomach.
  • Rejection reactions mean all reactions of the recipient body or of the transplanted organ which in the end lead to cell or tissue death in the transplanted organ or adversely affect the functional ability and viability of the transplanted organ or adversely affect the functional ability and viability of the transplanted organ or the recipient. In particular, this means acute and chronic rejection reactions.
  • Auto-immune disorders include, inter alia, systemic lupus erythematosus , rheumatoid arthritis, psoriasis, pemphigus, atopic dermatitis, myositis, multiple sclerosis, nephrotic syndrome (in particular glomerulonephritis) , ulcerative colitis or juvenile diabetes.
  • the invention further relates to the use of cyclosporin A or FK506 or Rapamycine and at least one pteridine derivative according to the invention for the production of a pharmaceutical composition for inhibiting the replication of viruses such as picorna-, toga-, bunya-, orthomyxo-, paramyxo- , rhabdo-, retro-, arena-, hepatitis B-, hepatitis C-, hepatitis D-, adeno-, vaccinia-, papilloma- , herpes-, varicella-zoster-virus or human immunodeficiency virus (HIV) ; or for treating of cancer such as lung cancers, leukaemia, ovarian cancers, sarcoma, Kaposi's sarcoma, meningioma, colon cancers, lymp node tumors, glioblastoma multiforme, prostate cancers or skin carcinoses .
  • viruses such as picorn
  • the invention further relates to the use of cyclosporin A or FK506 or rapa ycin and at least one pteridine derivative of the general formula (I) for the production of a pharmaceutical composition for the treatment of human after organ transplantation or of (auto) immune disorders.
  • the advantage to associate pteridine with other immunosuppressants may be that, first, the therapeutic spectrum of action of the individual components is quantitatively and qualitatively broadened. Secondly that it allows, by means of a dose reduction without reduced efficacy but with increased safety, that the treatment of immune disorders which were hitherto no indication for immunosuppressive therapy as a result of side effects may be considered. At the same time, the therapy costs can be decreased to an appreciable extent .
  • known pteridine derivatives are submitted to the same test conditions as the pteridine derivatives of the invention. These compounds and the results thereof are given in table IV and show no particular immunosuppressive activity.
  • the preparation according to the invention may contain the pteridine compounds over a broad content range depending on the contemplated use of the preparation.
  • the content of the preparation is within the range of 0.01-50 wt.%, preferably within the range of 0.01-10 wt.%, more preferably within the range of 0.1-10 wt.%, and most preferably within the range of 0.1-5 wt.%. Accordingly, the preparation may be used in a dosing regime which is suitable for most contemplated pharmaceutical utilities .
  • the preparation according to the invention may be used as such or in combination with any acceptable carrier material, excipient or diluent.
  • the preparation according to the invention may be administared orally or in any other suitable fashion. Oral administration is preferred and the preparation may have the form of a tablet, aqueous dispersion, dispersable powder or granule, emulsion, hard or soft capsule, syrup-, elixir or gel.
  • the dosing forms may be prepared using any method known in the art for manufacturing these pharmaceutical compositions and may comprise as additives sweeteners, flavoring agents, coloring agents, preservatives and the like.
  • Carrier materials and excipients may include calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, binding agents and the like.
  • the preparation may be included in a gelatin capsule mixed with any inert solid diluent or carrier material, or has the form of a soft gelatin capsule, in which the ingredient is mixed with a water or oil medium.
  • Aqueous dispersions may comprise the preparation in combination with a suspending agent, dispersing agent or wetting agent.
  • Oil dispersions may comprise suspending agents such as a vegetable oil.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00902660A 1999-02-02 2000-02-02 Immunodepressive effekte von pteridin-derivaten Withdrawn EP1187615A2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11828299P 1999-02-02 1999-02-02
US11829599P 1999-02-02 1999-02-02
US11823599P 1999-02-02 1999-02-02
US118235P 1999-02-02
US118282P 1999-02-02
US118295P 1999-02-02
PCT/EP2000/000938 WO2000045800A2 (en) 1999-02-02 2000-02-02 Immunosurpressive effects of pteridine derivatives

Publications (1)

Publication Number Publication Date
EP1187615A2 true EP1187615A2 (de) 2002-03-20

Family

ID=27382128

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00902660A Withdrawn EP1187615A2 (de) 1999-02-02 2000-02-02 Immunodepressive effekte von pteridin-derivaten

Country Status (5)

Country Link
EP (1) EP1187615A2 (de)
JP (1) JP2002536320A (de)
AU (1) AU780284B2 (de)
CA (1) CA2361561A1 (de)
WO (1) WO2000045800A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
ATE307121T1 (de) 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
AU2003258307A1 (en) 2002-08-20 2004-03-11 Neurogen Corp 5-substituted-2-arylpyrazines as modulators of crf receptors
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
CA2548172A1 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
EP2778156B8 (de) 2008-05-27 2017-02-22 AstraZeneca AB Phenoxypyridinylamidderivate und ihre Verwendung zur Behandlung von PDE4-vermittelten Krankheitszuständen
CA2974696A1 (en) 2015-01-22 2016-07-28 The Scripps Research Institute Pteridine dione monocarboxylate transporter inhibitors
EA035093B1 (ru) 2015-03-04 2020-04-27 Джилид Сайэнс, Инк. 4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы
ES2906581T3 (es) 2016-09-02 2022-04-19 Gilead Sciences Inc Compuestos moduladores de los receptores tipo Toll
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
AU2021299167B2 (en) * 2020-07-03 2024-03-21 Comvita Limited Anti-inflammatory compositions, methods and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204612B (it) * 1987-05-14 1989-03-10 Bioresearch Spa Pteridine atte alla preparazione di composizioni farmaceutiche ad attivita' antiamnesica
WO1993025712A1 (en) * 1992-06-15 1993-12-23 The Regents Of The University Of California Screening assay for the identification of immunosuppressive drugs
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
WO1994014065A1 (en) * 1992-12-14 1994-06-23 Dana-Farber Cancer Institute, Inc. Methods for identifying and using immunosuppressant compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5525711A (en) * 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
AU717243B2 (en) * 1994-12-29 2000-03-23 Regents Of The University Of California, The Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
WO1997039358A1 (en) * 1996-04-15 1997-10-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services In vitro prognostic test for progressors and non-progressors after hiv infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0045800A3 *

Also Published As

Publication number Publication date
WO2000045800A3 (en) 2002-01-10
WO2000045800A2 (en) 2000-08-10
AU780284B2 (en) 2005-03-10
CA2361561A1 (en) 2000-08-10
AU2441800A (en) 2000-08-25
JP2002536320A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
AU780284B2 (en) Immunosurpressive effects of pteridine derivatives
EP0956855B1 (de) Immununterdrückende Effekte von 8 substituierten Xanthinderivaten
US6946465B2 (en) Immunosuppressive effects of pteridine derivatives
EP1144412B1 (de) Immunsuppressive wirkungen von pteridinderivaten
JP4267697B2 (ja) 免疫抑制性化合物および方法
Allison Immunosuppressive drugs: the first 50 years and a glance forward
DE60025385T2 (de) 2,4-diaminopyrimidinderivate als immunosuppressiva
US6046328A (en) Combination preparation, containing cyclosporin A or FK506 or rapamycin and a xanthine derivative
EP1077715B1 (de) Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen
JPH0616674A (ja) 免疫抑制の誘導方法
JPH08512281A (ja) アデノシンａ▲下１▼受容体拮抗剤としてのキサンチン誘導体類
EP1161255A2 (de) Verfahren und mittel zur behandlung erektiler dysfunktion
Argyropoulos et al. Immunosuppressive drugs in HIV disease
US7253176B1 (en) Immunosuppressive effects of 8-substituted xanthine derivatives
AU757489B2 (en) Method for inhibiting cytokine production by cells
CA2519026A1 (en) Therapeutic and/or preventive agent for chronic skin disease
JP4194690B2 (ja) フェニルチアゾール骨格を有するプリンまたはピリミジンヌクレオシド取り込み阻害剤
JPH06234639A (ja) 免疫抑制剤
Carnaham et al. The use of immunosuppressive drugs in uveitis
Bach et al. Immunosuppressive therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010828

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 4 AZA BIOSCIENCE NV

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 4 AZA IP NV

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/13 20060101ALI20070509BHEP

Ipc: A61K 31/435 20060101ALN20070509BHEP

Ipc: A61P 37/00 20060101ALI20070509BHEP

Ipc: A61P 37/06 20060101ALI20070509BHEP

Ipc: A61K 31/42 20060101ALN20070509BHEP

Ipc: A61K 31/52 20060101ALI20070509BHEP

Ipc: A61K 31/57 20060101ALI20070509BHEP

Ipc: C07D 475/02 20060101ALI20070509BHEP

Ipc: A61K 31/505 20060101AFI20020131BHEP

Ipc: A61K 31/535 20060101ALI20070509BHEP

17Q First examination report despatched

Effective date: 20081002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090213